Share this article
SCOTTSDALE, Ariz., Feb. 3, 2021 /PRNewswire/ Matrix Medical Network
® (Matrix) today announced a collaboration with global biopharmaceutical company AstraZeneca to accelerate a clinical trial in the US for AZD7442, AstraZeneca s long-acting monoclonal antibody (LAAB) combination for the potential prevention of COVID-19. Matrix Clinical Solutions will meet eligible volunteers where they live and work with a fleet of Mobile Health Clinics and skilled clinicians, with a focus on populations more impacted by COVID-19.
Matrix Medical Network Mobile Health Clinic
Matrix is supporting the Phase III clinical trial called STORM CHASER, which will assess the safety and efficacy of AZD7442 for post-exposure prophylaxis in approximately 1,125 participants in the US and UK. Participants in this trial will include adults over 18 years of age following exposure to SARS-COV-2 and who are therefore at appreciable risk of developing COVID-19. The trial will include people liv